Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Bleomycin
/ administration & dosage
Brentuximab Vedotin
/ administration & dosage
Canada
Chemotherapy-Induced Febrile Neutropenia
/ epidemiology
Dacarbazine
/ administration & dosage
Doxorubicin
/ administration & dosage
Female
Follow-Up Studies
Hodgkin Disease
/ drug therapy
Humans
Kaplan-Meier Estimate
Lung Injury
/ chemically induced
Male
Middle Aged
Neoplasm Staging
Peripheral Nervous System Diseases
/ chemically induced
Progression-Free Survival
United States
Vinblastine
/ administration & dosage
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 03 2019
15 03 2019
Historique:
received:
04
09
2018
revised:
12
11
2018
accepted:
04
01
2019
pubmed:
9
1
2019
medline:
28
5
2020
entrez:
9
1
2019
Statut:
ppublish
Résumé
To evaluate safety and efficacy outcomes for subjects on the ECHELON-1 study treated in North America (NA). ECHELON-1 is a global, open-label, randomized phase III study comparing doxorubicin, vinblastine, and dacarbazine in combination with brentuximab vedotin (A+AVD) versus ABVD (AVD + bleomycin) as first-line therapy in subjects with stage III or IV classical Hodgkin lymphoma (cHL; NCT01712490). Subjects were randomized 1:1 to receive A+AVD or ABVD intravenously on days 1 and 15 of each 28-day cycle for up to 6 cycles. The NA subgroup consisted of 497 subjects in the A+AVD ( The efficacy benefit and manageable toxicity profile observed in the NA subgroup of ECHELON-1 support A+AVD as a frontline treatment option for patients with stage III or IV cHL.
Identifiants
pubmed: 30617130
pii: 1078-0432.CCR-18-2435
doi: 10.1158/1078-0432.CCR-18-2435
doi:
Substances chimiques
Bleomycin
11056-06-7
Vinblastine
5V9KLZ54CY
Dacarbazine
7GR28W0FJI
Brentuximab Vedotin
7XL5ISS668
Doxorubicin
80168379AG
Banques de données
ClinicalTrials.gov
['NCT01712490']
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1718-1726Informations de copyright
©2019 American Association for Cancer Research.